Thousands of Mexicans cross in the US on temporary visas to sell their blood plasma to profit-making pharmaceutical companies promising them hefty cash rewards.
Darryl Young suffered brain damage during a heart transplant and never woke up. Doctors kept him alive for a year to avoid federal scrutiny.
Human-animal hybrids are coming and could be used to grow organs for transplant. What does it mean? A philosopher weighs in
Evidence suggests that ever more people are putting cameras in a relative’s room to detect and deter abuse.
ECMO is designed to be a bridge to somewhere — recovery, transplantation or an implanted heart device. But for some patients it can be “bridge to nowhere.”
The change was welcomed by abortion opponents, who have long had fetal tissue research in their sights. Many scientists had a very different view.
Purdue Pharma considered capitalizing on the addiction treatment boom — while going to extreme lengths to boost sales of its controversial opioid.
Industry-sponsored research tends to be more positive than that financed by other sources, that in turn can sway which treatments become available to patients
Programs to screen the genomes of healthy adults to identify genes that may put them at risk for disease later in life need to be implemented with care so that they do not do more harm than good, says an expert panel.
This isn’t the first time a Chinese team has used the CRISPR technique on human embryos in a way that few researchers from other countries have attempted.
Surveys show that the public are optimistic about genome editing for curing diseases, but there can also be a lack of trust about how this technology will be used.
Top researchers at Memorial Sloan Kettering Cancer Center have filed at least six corrections with medical journals recently, divulging financial relationships with health care companies that they did not previously disclose.
The Trump administration faces mounting pressure from conservative lawmakers and abortion opponents to halt the use of tissue obtained from aborted fetuses.
The center’s pathologists have objected to the deal, saying it is unfair that the founders received equity that relies on the pathologists’ expertise and work
Universities that sell access to their biobanks to private companies should tell patients and be transparent about how profits are used, a new survey shows.